IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Tue, 20th Apr 2021 12:17

Avacta Group PLC - Yorkshire-based drug and medical equipment maker - Lateral flow test for Covid-19 is shown to have 98% sensitivity in clinical study. 20-minute AffiDX test correctly identified 96 out of 98 positive samples of virus and 101 out of 102 negative samples. Test effective on a range of viral loads. Company will file for a CE mark in May and start commercial roll-out in coming months.

Current stock price: 261.69 pence, up 12% on Tuesday

Year-to-date change: more than doubled from 114p on December 31

By Ivan Edwards; ivanedwards@alliancenews.com

Related Shares

More News

1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thur...